Center of Neuroimmunology and Department of Neurology, Advanced Imaging in Neuroimmunological Diseases group (ImaginEM), Service of Neurology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
Center of Neuroimmunology and Department of Neurology, Advanced Imaging in Neuroimmunological Diseases group (ImaginEM), Service of Neurology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Department of Neurology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain.
Mult Scler. 2021 Oct;27(11):1706-1716. doi: 10.1177/1352458520981910. Epub 2021 Jan 12.
Prognostic markers are needed to guide multiple sclerosis (MS) management in the context of large availability of disease-modifying drugs (DMDs).
To investigate the role of cerebrospinal fluid (CSF) markers to inform long-term MS outcomes.
Demographic features, IgM index, oligoclonal IgM bands (OCMB), lipid-specific OCMB, CSF neurofilament light chain protein levels, expanded disability status scale (EDSS), relapses and DMD use over the study period and peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell plus inner plexiform layer (GCIPL) thicknesses in non-optic neuritis eyes (end of follow-up) were collected from relapsing MS (RMS) patients with CSF obtained ⩽2 years after MS onset prospectively followed at the Hospital Clinic of Barcelona. We assessed associations between CSF markers and MS outcomes using multivariable models.
A total of 89 patients (71 females; median 32.9 years of age) followed over a median of 9.6 years were included. OCMB were associated with a 33% increase in the annualized relapse rate (ARR; = 0.06), higher odds for high-efficacy DMDs use (OR = 4.8; 95% CI = (1.5, 16.1)), thinner pRNFL (β = -4.4; 95% CI = (-8.6, -0.2)) and GCIPL (β = -2.9; 95% CI = (-5.9, +0.05)), and higher rates to EDSS ⩾ 3.0 (HR = 4.4; 95% CI = (1.6, 11.8)) and EDSS ⩾ 4.0 (HR = 5.4; 95% CI = (1.1, 27.1)). No overall associations were found for other CSF markers.
The presence of OCMB was associated with unfavorable long-term outcomes. OCMB should be determined in RMS to inform long-term prognosis.
在大量疾病修饰药物 (DMD) 可用的情况下,需要预后标志物来指导多发性硬化症 (MS) 的治疗。
研究脑脊液 (CSF) 标志物在预测 MS 长期预后中的作用。
前瞻性收集巴塞罗那 Clinic 医院随访的复发型 MS (RMS) 患者的人口统计学特征、IgM 指数、寡克隆 IgM 带 (OCMB)、脂质特异性 OCMB、CSF 神经丝轻链蛋白水平、扩展残疾状况量表 (EDSS)、复发次数和 DMD 使用情况,以及非视神经炎眼的视盘周围神经纤维层 (pRNFL) 和节细胞内丛状层 (GCIPL) 厚度 (随访结束时)。采用多变量模型评估 CSF 标志物与 MS 结局之间的关系。
共纳入 89 例患者(71 例女性;中位年龄 32.9 岁),中位随访时间为 9.6 年。OCMB 与年复发率 (ARR) 增加 33%相关 ( = 0.06),使用高效 DMD 的几率更高 (OR = 4.8;95%CI = (1.5, 16.1)),pRNFL 更薄 (β = -4.4;95%CI = (-8.6, -0.2))和 GCIPL (β = -2.9;95%CI = (-5.9, +0.05)),EDSS ⩾ 3.0 (HR = 4.4;95%CI = (1.6, 11.8))和 EDSS ⩾ 4.0 (HR = 5.4;95%CI = (1.1, 27.1))的发生率更高。其他 CSF 标志物与总体结果无相关性。
OCMB 的存在与不良的长期预后相关。应在 RMS 中确定 OCMB,以预测长期预后。